These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 11369820

  • 1. Angiotensin II AT(1) receptor antagonists and platelet activation.
    López-Farré A, Sánchez de Miguel L, Montón M, Jiménez A, Lopez-Bloya A, Gómez J, Núñez A, Rico L, Casado S.
    Nephrol Dial Transplant; 2001; 16 Suppl 1():45-9. PubMed ID: 11369820
    [Abstract] [Full Text] [Related]

  • 2. Inhibition of platelet activation in stroke-prone spontaneously hypertensive rats: comparison of losartan, candesartan, and valsartan.
    Jiménez AM, Montón M, García R, Núñez A, Gómez J, Rico L, García-Colis E, de Miguel LS, Arriero MM, Cabestrero F, Farré J, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2001 Apr; 37(4):406-12. PubMed ID: 11300653
    [Abstract] [Full Text] [Related]

  • 3. Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
    Montón M, Jiménez A, Núñez A, López-Blaya A, Farré J, Gómez J, Zalba LR, Sánchez de Miguel L, Casado S, López-Farré A.
    J Cardiovasc Pharmacol; 2000 Jun; 35(6):906-13. PubMed ID: 10836725
    [Abstract] [Full Text] [Related]

  • 4. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats.
    Li P, Ferrario CM, Brosnihan KB.
    J Cardiovasc Pharmacol; 1998 Aug; 32(2):198-205. PubMed ID: 9700980
    [Abstract] [Full Text] [Related]

  • 5. Angiotensin receptor blocker losartan suppresses platelet activity by interfering with thromboxane signaling.
    Schwemmer M, Sommer O, Bassenge E.
    Cardiovasc Drugs Ther; 2001 Jul; 15(4):301-7. PubMed ID: 11800413
    [Abstract] [Full Text] [Related]

  • 6. [Effect of losartan on human platelet activation by thromboxane A2].
    Guerra JI, Montón M, Rodríguez-Feo JA, Farré J, Jiménez AM, Núñez A, Gómez J, Rico L, Marcos P, Castilla C, Sánchez De Miguel L, Casado S, López-Farré A.
    Rev Esp Cardiol; 2000 Apr; 53(4):525-30. PubMed ID: 10758030
    [Abstract] [Full Text] [Related]

  • 7. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [Abstract] [Full Text] [Related]

  • 8. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan.
    Núñez A, Gómez J, Zalba LR, Montón M, Jiménez A, Velasco S, López-Blaya A, Uriarte AC, Casado S, López-Farré A.
    J Renin Angiotensin Aldosterone Syst; 2000 Jun; 1(2):175-9. PubMed ID: 11967810
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Studies on the antithrombotic action of AT1 receptor antagonists.
    Buczko W, Matys T, Pawlak R, Kucharewicz I, Chabielska E.
    Med Sci Monit; 2001 Jun; 7(4):600-5. PubMed ID: 11433183
    [Abstract] [Full Text] [Related]

  • 12. Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release.
    Kalinowski L, Matys T, Chabielska E, Buczko W, Malinski T.
    Hypertension; 2002 Oct; 40(4):521-7. PubMed ID: 12364357
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
    Nossaman BD, Baber SR, Nazim MM, Detrolio JD, Kadowitz PJ.
    Can J Physiol Pharmacol; 2007 Oct; 85(3-4):360-71. PubMed ID: 17612645
    [Abstract] [Full Text] [Related]

  • 15. Losartan reduces constrictor responses to endothelin-1 and the thromboxane A2 analogue in aortic rings from spontaneously hypertensive rats: role of nitric oxide.
    Maeso R, Rodrigo E, Muñoz-Garcia R, Navarro-Cid J, Ruilope LM, Lahera V, Cachofeiro V.
    J Hypertens; 1997 Dec; 15(12 Pt 2):1677-84. PubMed ID: 9488222
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antagonistic effects of losartan on thromboxane A2-receptors in human isolated gastroepiploic artery and saphenous vein.
    Tripodi F, Stanke-Labesque F, Devillier P, Chavanon O, Sessa C, Bessard G.
    J Cardiovasc Pharmacol; 1999 Nov; 34(5):734-40. PubMed ID: 10547091
    [Abstract] [Full Text] [Related]

  • 19. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
    Mazzolai L, Maillard M, Rossat J, Nussberger J, Brunner HR, Burnier M.
    Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
    [Abstract] [Full Text] [Related]

  • 20. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries.
    Li P, Ferrario CM, Brosnihan KB.
    J Pharmacol Exp Ther; 1997 Jun; 281(3):1065-70. PubMed ID: 9190837
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.